Skip to main content
SpringerLink
Log in

18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease

  • Chapter
  • First Online:
PET/CT in Brain Disorders

Part of the book series: Clinicians’ Guides to Radionuclide Hybrid Imaging ((PET/CT))

Abstract

Neurodegenerative diseases are a heterogeneous group of conditions due to different etiologies and different neuropathological and neurochemical alterations leading to different clinical pictures and courses.

With its peculiar ability to noninvasively reflect cerebral synaptic density and activity, FDG-PET plays a major role in evaluating the extent and localization of neuronal dysfunction, thus characterizing the endophenotype of a neuronal injury.

The identification of typical patterns of hypometabolism since the earliest stages of neurodegenerative diseases can support clinicians in differential diagnosis, especially in atypical and challenging cases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Nasrallah IM, Wolk DA. Multimodality imaging of Alzheimer disease and other neurodegenerative dementias. J Nucl Med. 2014;55:2003–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Kovacs GG. Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine. Int J Mol Sci. 2016;17:189.

    PubMed Central  Google Scholar 

  3. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol. 1999;45:358–68.

    CAS  PubMed  Google Scholar 

  4. Rocher AB, Chapon F, Blaizot X, Baron JC, Chavoix C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. NeuroImage. 2003;20:1894–8.

    PubMed  Google Scholar 

  5. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–46.

    PubMed  Google Scholar 

  6. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9.

    PubMed  PubMed Central  Google Scholar 

  7. Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9:414–21.

    PubMed  Google Scholar 

  8. Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77:2034–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Sorbi S, Hort J, Erkinjuntti T, Fladby T, Gainotti G, Gurvit H, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19:1159–79.

    CAS  PubMed  Google Scholar 

  10. Filippi M, Agosta F, Barkhof F, Dubois B, Fox NC, Frisoni GB, et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol. 2012;19:1487–501.

    Google Scholar 

  11. Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103–10.

    PubMed  Google Scholar 

  12. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage. 2002;17:302–16.

    CAS  PubMed  Google Scholar 

  13. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol. 2007;80:S160–7.

    PubMed  Google Scholar 

  14. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008;49:390–8.

    PubMed  PubMed Central  Google Scholar 

  15. Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH, Vach W, et al. [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology. 2012;79:1314–22.

    CAS  PubMed  Google Scholar 

  16. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238–48.

    CAS  PubMed  Google Scholar 

  17. Gallucci M, Limbucci N, Catalucci A, Caulo M. Neurodegenerative diseases. Radiol Clin N Am. 2008;46:799–817.

    PubMed  Google Scholar 

  18. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486–510.

    CAS  PubMed  Google Scholar 

  19. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42:85–94.

    CAS  PubMed  Google Scholar 

  20. Morbelli S, Piccardo A, Villavecchia G, Dessi B, Brugnolo A, Piccini A, et al. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. Eur J Nucl Med Mol Imaging. 2010;37:36–45.

    PubMed  Google Scholar 

  21. Ohnishi T, Hoshi H, Nagamachi S, Jinnouchi S, Flores LG II, Futami S, et al. High-resolution SPECT to assess hippocampal perfusion in neuropsychiatric diseases. J Nucl Med. 1995;36:1163–9.

    CAS  PubMed  Google Scholar 

  22. Kim EJ, Cho SS, Jeong Y, Park KC, Kang SJ, Kang E, et al. Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain. 2005;128:1790–801.

    CAS  PubMed  Google Scholar 

  23. Morbelli S, Perneczky R, Drzezga A, Frisoni GB, Caroli A, van Berckel BN, et al. Metabolic networks underlying cognitive reserve in prodromal Alzheimer disease: a European Alzheimer disease consortium project. J Nucl Med. 2013;54:894–902.

    CAS  PubMed  Google Scholar 

  24. Madhavan A, Whitwell JL, Weigand SD, Duffy JR, Strand EA, Machulda MM, et al. FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimer's type. PLoS One. 2013;8:e62471.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Laforce R Jr, Tosun D, Ghosh P, Lehmann M, Madison CM, Weiner MW, et al. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer’s pathology. Neuroimage Clin. 2014;4:508–16.

    PubMed  PubMed Central  Google Scholar 

  26. Rosenbloom MH, Alkalay A, Agarwal N, Baker SL, O'Neil JP, Janabi M, et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology. 2011;76:1789–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Woodward MC, Rowe CC, Jones G, Villemagne VL, Varos TA. Differentiating the frontal presentation of Alzheimer’s disease with FDG-PET. J Alzheimers Dis. 2015;44:233–42.

    PubMed  Google Scholar 

  28. Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551–67.

    PubMed  PubMed Central  Google Scholar 

  29. Kerrouche N, Herholz K, Mielke R, Holthoff V, Baron JC. 18FDG PET in vascular dementia: differentiation from Alzheimer’s disease using voxel-based multivariate analysis. J Cereb Blood Flow Metab. 2006;26:1213–21.

    CAS  PubMed  Google Scholar 

  30. Seltman RE, Matthews BR. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs. 2012;26:841–70.

    CAS  PubMed  Google Scholar 

  31. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77.

    PubMed  PubMed Central  Google Scholar 

  32. Whitwell JL, Josephs KA. Neuroimaging in frontotemporal lobar degeneration—predicting molecular pathology. Nat Rev Neurol. 2012;8:131–42.

    CAS  PubMed  Google Scholar 

  33. Morbelli S, Ferrara M, Fiz F, Dessi B, Arnaldi D, Picco A, et al. Mapping brain morphological and functional conversion patterns in predementia late-onset bvFTD. Eur J Nucl Med Mol Imaging. 2016;43:1337–47.

    PubMed  Google Scholar 

  34. Mendez MF, Shapira JS, McMurtray A, Licht E, Miller BL. Accuracy of the clinical evaluation for frontotemporal dementia. Arch Neurol. 2007;64:830–5.

    PubMed  Google Scholar 

  35. Chow TW, Miller BL, Boone K, Mishkin F, Cummings JL. Frontotemporal dementia classification and neuropsychiatry. Neurologist. 2002;8:263–9.

    PubMed  PubMed Central  Google Scholar 

  36. Jeong Y, Cho SS, Park JM, Kang SJ, Lee JS, Kang E, et al. 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med. 2005;46:233–9.

    PubMed  Google Scholar 

  37. Womack KB, Diaz-Arrastia R, Aizenstein HJ, Arnold SE, Barbas NR, Boeve BF, et al. Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. Arch Neurol. 2011;68:329–37.

    PubMed  Google Scholar 

  38. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–14.

    PubMed  PubMed Central  Google Scholar 

  39. Matías-Guiu JA, Cabrera-Martín MN, Moreno-Ramos T, Valles-Salgado M, Fernandez-Matarrubia M, Carreras JL, et al. Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes. J Neurol. 2015;262:1463–72.

    PubMed  Google Scholar 

  40. Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64:388–401.

    PubMed  PubMed Central  Google Scholar 

  41. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100.

    PubMed  PubMed Central  Google Scholar 

  42. Bauckneht M, Arnaldi D, Nobili F, Aarsland D, Morbelli S. New tracers and new perspectives for molecular imaging in Lewy body diseases. Curr Med Chem. 2018;25(26):3105–30.

    CAS  PubMed  Google Scholar 

  43. Graff-Radford J, Murray ME, Lowe VJ, Boeve BF, Ferman TJ, Przybelski SA, et al. Dementia with Lewy bodies: basis of cingulate island sign. Neurology. 2014;83:801–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Pagani M, Chiò A, Valentini MC, Öberg J, Nobili F, Calvo A, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067–74.

    CAS  PubMed  Google Scholar 

  45. Prado LGR, Bicalho ICS, Magalhães D, Caramelli P, Teixeira AL, de Souza LC. C9ORF72 and the FTD-ALS spectrum: A systematic review of neuroimaging studies. Dement Neuropsychol. 2015;9:413–21.

    PubMed  PubMed Central  Google Scholar 

  46. Magistretti PJ. Cellular bases of functional brain imaging: insights from neuron-glia metabolic coupling. Brain Res. 2000;886:108–12.

    CAS  PubMed  Google Scholar 

  47. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29.

    PubMed  Google Scholar 

  48. Morbelli S, Bauckneht M, Arnaldi D, Picco A, Pardini M, Brugnolo A, et al. 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer’s disease (AD) patients at the mild cognitive impairment (MCI) stage. Eur J Nucl Med Mol Imaging. 2017;44:2073–83.

    PubMed  Google Scholar 

  49. Morbelli S, Bauckneht M, Scheltens P. Imaging biomarkers in Alzheimer’s disease: added value in the clinical setting. Q J Nucl Med Mol Imaging. 2017;61:360–71.

    PubMed  Google Scholar 

  50. Perani D, Della Rosa PA, Cerami C, Gallivanone F, Fallanca F, Vanoli EG, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin. 2014;6:445–54.

    PubMed  PubMed Central  Google Scholar 

  51. Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C. 18F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;1:CD010632.

    PubMed  Google Scholar 

  52. Morbelli S, Garibotto V, Van De Giessen E, Arbizu J, Chételat G, Drezgza A, et al. A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives. Eur J Nucl Med Mol Imaging. 2015;42:1487–91.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Health Sciences (DiSSAL), University of Genoa and Nuclear Medicine Unit, Polyclinic San Martino Hospital, Genoa, Italy

    Selene Capitanio, Matteo Bauckneht, Valentina Ceriani & Silvia Morbelli

  2. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Mother-Child Health (DINOGMI), Clinical Neurology, Polyclinic San Martino Hospital, University of Genoa, Genoa, Italy

    Dario Arnaldi, Federico Massa, Riccardo Meli & Flavio Nobili

Authors
  1. Selene Capitanio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matteo Bauckneht
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dario Arnaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Federico Massa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Riccardo Meli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Valentina Ceriani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Flavio Nobili
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Silvia Morbelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvia Morbelli .

Editor information

Editors and Affiliations

  1. Institute of Nuclear Medicine, University College London, London, UK

    Francesco Fraioli

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Capitanio, S. et al. (2019). 18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease. In: Fraioli, F. (eds) PET/CT in Brain Disorders. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-030-01523-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-01523-7_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-01522-0

  • Online ISBN: 978-3-030-01523-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation